Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refract…

NPM1 mutations, one of the most common genetic drivers of AML, are now actionable for patients –– Acute unmet need in R/R ...